Perceptive Advisors-sponsored SPAC agrees to deal with Bain Capital-backed Cerevel Therapeutics

In addition to the $150m from Arya II, a group of healthcare investors committed to participate in the deal through a common stock private investment in public equity of about $320m at $10 per share.